169 - The Changing Landscape of Human Papilloma Virus Prevention

Friday, October 21, 2022

1:45 PM – 3:00 PM US ET

Location: 202 AB

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Christine Johnston, MD, MPH

Associate Professor
Medicine
University of Washington
Seattle, Washington, United States

Disclosure(s): Abbvie: Advisor/Consultant (Terminated); Gilead Biosciences: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); GSK: Advisor/Consultant (Ongoing); UpToDate Wolters Kluwer Health: Royalties (Ongoing)
Helen Stankiewicz Karita, MD, MSc

Acting Assistant Professor, Infectious Diseases
University of Washington
Seattle, Washington, United States

Disclosure(s): No financial relationships to disclose

Faculty(s)

Joel Palefsky, MD

Professor of Medicine
University of California, San Francisco
San Francisco, CA, United States

Disclosure(s): Antiva Biosciences: Advisor/Consultant (Ongoing); Gilead Biosciences: Honoraria (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Vir Biotechnologies: Advisor/Consultant (Ongoing); Virion Therapeutics: Advisor/Consultant (Ongoing), Stock options (Ongoing)

Slides
Ruanne Barnabas, MBChB, MSc, DPhil

Chief, Division of Infectious Diseases
Massachusetts General Hospital
Boston, MA, United States

Disclosure(s): Regeneron Pharmaceuticals, Inc.: Regeneron covered the cost of conference abstract and manuscript writing (Ongoing)

Slides
Anna Giuliano, PhD

Senior Member and Director
Moffitt Cancer Center
Tampa, FL, United States

Disclosure(s): Immunomic Therapeutics: Advisor/Consultant (Ongoing); LinKinVax: Advisor/Consultant (Ongoing); Merck & Co. Inc: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing)

Slides

Disclosure(s):

Christine Johnston, MD, MPH: Abbvie: Advisor/Consultant (Terminated); Gilead Biosciences: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); GSK: Advisor/Consultant (Ongoing); UpToDate Wolters Kluwer Health: Royalties (Ongoing)

Helen C. Stankiewicz Karita, MD, MSc: No financial relationships to disclose

Joel Palefsky, MD: Antiva Biosciences: Advisor/Consultant (Ongoing); Gilead Biosciences: Honoraria (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Vir Biotechnologies: Advisor/Consultant (Ongoing); Virion Therapeutics: Advisor/Consultant (Ongoing), Stock options (Ongoing)

Ruanne Barnabas, MBChB, MSc, DPhil: Regeneron Pharmaceuticals, Inc.: Regeneron covered the cost of conference abstract and manuscript writing (Ongoing)

Anna R. Giuliano, PhD: Immunomic Therapeutics: Advisor/Consultant (Ongoing); LinKinVax: Advisor/Consultant (Ongoing); Merck & Co. Inc: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing)

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe evidence-based strategies to prevent anal cancer among people with HIV;
outline novel HPV dosing schedules to optimize cervical cancer prevention worldwide;
describe approaches to oropharyngeal HPV prevention, screening, diagnosis and treatment

Presentations:

1:45 PM – 2:10 PM US ET

Anal Cancer Prevention: How the ANCHOR Study Should Change Your Practice
Speaker: Joel Palefsky, MD – University of California, San Francisco
2:10 PM – 2:35 PM US ET

Stopping the Spread of HPV Globally: The KEN SHE Trial and Improved Access to HPV Vaccines
Speaker: Ruanne Barnabas, MBChB, MSc, DPhil – Massachusetts General Hospital
2:35 PM – 3:00 PM US ET

Prevention of HPV-Associated Oropharyngeal Cancer: Vaccination and Screening
Speaker: Anna R. Giuliano, PhD – Moffitt Cancer Center